Curis, Debiopharm Start Phase I Study Of Debio 0932 With Everolimus RTT News Curis, Inc.(CRIS: Quote), and Debiopharm Group Tuesday announced the start of a Phase I dose-finding study of Debio 0932, a heat shock protein 90 inhibitor in combination with everolimus, an inhibitor of mammalian target of rapamycin, in patients with ... |
